Pulmonary and intracranial radiographic presentations of Langerhans Cell Histiocytosis

Denelle Mohammed; Samarth B. Patel

Background. Langerhans Cell Histiocytosis is a rare disease that affects 1 to 2 adults per million worldwide and often consists of systemic manifestations including pulmonary, intracranial and osteolytic lesions and endocrinologic abnormalities such as Diabetes Insipidus. Objective. The objective of this case report was to expand the medical literature of this rare disease. Methods. A case report of a 51-year-old female patient presenting with systemic symptoms as a result of Langerhans Cell Histiocytosis is presented. Results. A 51-year-old female presented with epistaxis, fatigue, polydipsia, polyuria, headaches and dyspnea. After initial x-rays showed multiple lung and liver nodules and the patient suffered subsequently from a unilateral pneumothorax, an open lung biopsy was recommended. On a pathological basis, the patient was diagnosed with Langerhans Cell Histiocytosis. This report focuses on the radiological presentations of the manifestations of Langerhans Cell Histiocytosis, particularly the presentations in the lung and intracranial regions. Conclusions. Langerhans Cell Histiocytosis is an incredibly rare disease that presents systemically. Recognizing and differentiating radiographic presentation of these patients is important to determine the need for confirmation by biopsy and early chemotherapeutic intervention

Langerhans Cell Histiocytosis, FDG-PET (positron emission with 18F-2-deoxy-D-glucose (FDG), MRI (magnetic resonance imaging), X-ray

[1] Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol. 1997;28(1):9-14.doi: 10.1002/(SICI)1096-911X(199701)28:1<9::AID-MPO3>3.0.CO;2-P

[2] Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol. 2008;8(12):935-47.doi: 10.1038/nri2455

[3] Egeler RM, van Halteren AG, Hogendoorn PC, Laman JD, Leenen PJ. Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macro-phage lineage. Immunol Rev. 2010;234(1):213-32.doi: 10.1111/j.0105-2896.2009.00883.x

[4] Brown NA, Furtado LV, Betz BL, Kiel MJ, weigelin HC, Lim MS, Elenitoba-Johnson KS. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655-8.doi: 10.1182/blood-2014-05-577361

[5] Roden AC, yi ES. Pulmonary Langerhans cell histiocytosis: an update from the pathologists' perspective. Archives of pathology & laboratory medicine. 2016;140(3):230-40.doi: 10.5858/arpa.2015-0246-RA

[6] Annibali S, Cristalli MP, Solidani M, Ciavarella D, La Monaca G, Suriano MM, Lo Muzio L, Lo Russo L. Langerhans cell histiocytosis: oral/periodontal involvement in adult patients. Oral diseases. 2009 Nov;15(8):596-601.doi: 10.1111/j.1601-0825.2009.01601.x

[7] Braier JL, Rosso D, Latella A, Chantada G, Ozuna B, Ripoli M, Scopinaro M. Importance of multi-lineage hematologic involvement and hypoal-buminemia at diagnosis in patients with “risk-organ” multi-system Langerhans cell histiocytosis. Journal of pediatric hematology/oncology. 2010 May 1;32(4):e122-5.doi: 10.1097/MPH.0b013e3181d7acc5

[8] Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, Lassmann H, Nanduri V, Prosch H, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. The Journal of pediatrics. 2010 Jun 1;156(6):873-81.doi: 10.1016/j.jpeds.2010.03.001

[9] Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, Monson JP, Besser GM, Grossman AB. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. The Journal of Clinical Endocrinology & Metabolism. 2000 Apr 1;85(4):1370-6.doi: 10.1210/jcem.85.4.6501

[10] Mittheisz E, Seidl R, Prayer D, waldenmair M, Neophytou B, Pötschger U, Minkov M, Steiner M, Prosch H, wnorowski M, Gadner H. Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis. Pediatric blood & cancer. 2007 Jan;48(1):50-6.doi: 10.1002/pbc.20760

[11] Maghnie M, Genovese E, Bernasconi S, Binda S, Arico M. Persistent high MR signal of the posterior pituitary gland in central diabetes insipidus. AJNR Am J Neuroradiol. 1997;18:1749-52.http://www.ajnr.org/content/ajnr/18/9/1749.full.pdf

[12] Prayer D, Grois N, Prosch H, Gadner H, and Barkovich AJ. MR Imaging Presentation of Intracranial Disease Associated with Langerhans Cell Histiocytosis. AJNR Am J Neuroradiol. 2004;25:880-91.http://www.ajnr.org/content/25/5/880.long

[13] Ganong WF. Circumventricular organs: definition and role in the regulation of endocrine and autonomic function. Clin Exp Pharmacol Physiol. 2000;27:422-7.doi: 10.1046/j.1440-1681.2000.03259.x

[14] Odame I, Li P, Lau L, Doda w, Noseworthy M, Babyn P, weitzman S. Pulmonary Langerhans cell histiocytosis: a variable disease in childhood. Pediatric blood & cancer. 2006 Dec 1;47(7):889-93.doi: 10.1002/pbc.20676

[15] Samanci NS, Ayer M. Multisystem involvement of Langerhans cell histiocytosis in an adult. The Indian journal of medical research. 2019;149:78.doi: 10.4103/ijmr.IJMR_1726_17

[16] Kulwiec EL, Lynch DA, Aguayo SM, Schwarz MI, King Jr T. Imaging of pulmonary histiocytosis X. Radiographics. 1992;12:515-26.doi: 10.1148/radiographics. 12.3.1609142

[17] Castoldi MC, Verrioli A, De Juli E, Vanzulli A. Pulmonary Langerhans cell histiocytosis: the many faces of presentation at initial CT scan. Insights into imaging. 2014;5:483-92.doi: 10.1007/s13244-014-0338-0

[18] Krajicek BJ, Ryu JH, Hartman TE, Lowe VJ, Vassallo R. Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest. 2009;135:1542-9.doi: 10.1378/chest.08-1899